Literature DB >> 1601980

Interferon-gamma regulation of C3 gene expression in human astroglioma cells.

S R Barnum1, J L Jones, E N Benveniste.   

Abstract

In this report, we show that the human astroglioma cell line, D54-MG, constitutively expresses C3 mRNA and secretes antigenically detectable C3 protein. The cytokine interferon-gamma (IFN-gamma) enhances C3 mRNA and protein expression by D54-MG cells in a dose- and time-dependent manner. C3 mRNA from both D54-MG cells and primary human adult astrocytes has the same apparent size (5.1-5.2 kb) as C3 mRNA from hepatocyte and monocyte cell lines. Constitutive C3 mRNA levels in D54-MG cells and primary human astrocytes are comparable. Primary rat astrocytes also constitutively express C3 mRNA, which is enhanced upon exposure to IFN-gamma. These data are novel since expression of C3 in other cell types is refractory to IFN-gamma. In the central nervous system (CNS), endogenous complement production by astrocytes, and enhancement by the cytokine IFN-gamma, may contribute to the pathogenesis of inflammatory demyelinating diseases such as multiple sclerosis (MS).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1601980     DOI: 10.1016/0165-5728(92)90020-l

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

Review 1.  Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities.

Authors:  Philippe Gasque; Jim W Neal; Sim K Singhrao; Eamon P McGreal; Yann D Dean; Beek Johan Van; B Paul Morgan
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

2.  IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice.

Authors:  Paramita Chakrabarty; Carolina Ceballos-Diaz; Amanda Beccard; Christopher Janus; Dennis Dickson; Todd E Golde; Pritam Das
Journal:  J Immunol       Date:  2010-04-05       Impact factor: 5.422

3.  Induction of the chemokines interleukin-8 and IP-10 by human immunodeficiency virus type 1 tat in astrocytes.

Authors:  O Kutsch; J Oh; A Nath; E N Benveniste
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

4.  Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor.

Authors:  N J Van Wagoner; J W Oh; P Repovic; E N Benveniste
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

5.  Role of C/EBP-β, p38 MAPK, and MKK6 in IL-1β-mediated C3 gene regulation in astrocytes.

Authors:  Jeffrey Maranto; Jay Rappaport; Prasun K Datta
Journal:  J Cell Biochem       Date:  2011-04       Impact factor: 4.429

6.  Envelope glycoprotein gp120 of human immunodeficiency virus type 1 alters ion transport in astrocytes: implications for AIDS dementia complex.

Authors:  D J Benos; B H Hahn; J K Bubien; S K Ghosh; N A Mashburn; M A Chaikin; G M Shaw; E N Benveniste
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

7.  The role of the complement system and the activation fragment C5a in the central nervous system.

Authors:  Trent M Woodruff; Rahasson R Ager; Andrea J Tenner; Peter G Noakes; Stephen M Taylor
Journal:  Neuromolecular Med       Date:  2009-09-11       Impact factor: 3.843

8.  Regulation of complement component C3 in astrocytes by IL-1beta and morphine.

Authors:  Jeffrey Maranto; Jay Rappaport; Prasun K Datta
Journal:  J Neuroimmune Pharmacol       Date:  2007-11-14       Impact factor: 4.147

9.  Downregulation of constitutive and cytokine-induced complement 3 expression by morphine in rat astrocytes.

Authors:  Chung Su Kim; Justin Sangwook Ko; Ae Ryoung Lee; Byung Seop Shin; Soo Joo Choi; Jeong Jin Lee; Hyun Soo Kim; Sangmin Maria Lee
Journal:  Curr Ther Res Clin Exp       Date:  2011-02

10.  CAWS administration increases the expression of interferon γ and complement factors that lead to severe vasculitis in DBA/2 mice.

Authors:  Noriko Nagi-Miura; Daisuke Okuzaki; Kosuke Torigata; Minami A Sakurai; Akihiko Ito; Naohito Ohno; Hiroshi Nojima
Journal:  BMC Immunol       Date:  2013-09-24       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.